PRELIMINARY AMENDMENT

Serial No.: 09/610,891

The vaccine of claim 37, wherein said host cell further comprises a nucleic acid encoding a cytokine.

[]]

The vaccine of claim 32, wherein said cytokine is GM-CSF.

The vaccine of claim 30, further comprising a second cell comprising a nucleic acid encoding a cytokine.

The vaccine of claim 34, wherein said cytokine is GM-CSF.--

Rad C1

<u>REMARKS</u>

The instant specification teaches tumor-associated antigens that elicit a humoral response when administered as a cellular vaccine using a cell that does not divide in conjunction with a cytokine; see page 24, second full paragraph. No issue of new matter is raised by the above-added new claims and entry thereof is requested respectfully.

In a telephone Restriction Requirement, the Examiner indicated that claims 1-22 as filed were divisible into three groups of claims:

- I. claims 1-10 drawn to a method of identifying an antigen;
- II. claims 11-15 drawn to a method of screening for an antigen; and
- III. claims 16-22 drawn to kits.

PRELIMINARY AMENDMENT Serial No.: 09/610,891

Applicants herein elect without traverse for examination on the merits in the instant application, newly added claims 23-35. Claims 23-35 relate to a vaccine and constitute a group distinct from Groups I-III. The non-elected claims 1-22 have been removed from the instant application for prosecution in divisions.

Favorable consideration and early indication of allowance are solicited earnestly.

Respectfully submitted,

Dean H. Nakamura Attorney for Applicants

Reg. No. 33,981

Roylance, Abrams, Berdo & Goodman L.L.P. 1300 19th Street, N.W., Suite 600 Washington, D.C. 20036-2680 (202) 659-9076

Dated: 25 June 2001

The undersigned hereby certifies that the instant Preliminary Amendment of four pages was transmitted by facsimile to the U.S. Patent and Trademark Office on 25 June 2001.

Dean H. Nakamura Reg. No. 33,981